Loading
The receptor that tells the bone marrow to make neutrophils. Filgrastim and pegfilgrastim stimulate it to shorten the dangerous low-neutrophil period after chemotherapy, cutting the risk of febrile neutropenia. This dossier gathers the 2 products (1 approved), 4 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Cytokine receptor on neutrophil progenitors signalling through JAK2 and STAT3; agonised by recombinant G-CSF.
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Myeloproliferative neoplasms | 59% | Activating CSF3R mutation in chronic neutrophilic leukaemia or atypical BCR-ABL1-negative CML, 16 of 27 patients | Two mutation regions with different kinase dependencies (SRC family or JAK); ruxolitinib response reported in a JAK-type case | doi.org |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
| Modality | Approved | Withdrawn or failed |
|---|---|---|
| Antibody 1 | - | |
| Recombinant glycosylated G-CSF, injection 1 | - |
| Trial | Setting | Result | Products | ||
|---|---|---|---|---|---|
| 3 | Completed | A Multicenter Randomized Study Comparing the Dose Dense, G-CSF-Supported Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Women With Axillary Lymph Node Positive Breast Cancer | - | ||
| 3 | Completed | A Multicenter Randomized Study Comparing the Dose Dense, G-CSF-supported Sequential Administration of FE75C Followed by Docetaxel Versus Docetaxel/Cyclophosphamide Doublet as Adjuvant Chemotherapy in Women With HER-2 Negative, Axillary Lymph Node Positive Breast Cancer | - | ||
| 3 | Completed | A Multicenter Randomized Phase III Study Comparing 6 Versus 12 Months of Trastuzumab in Combination With Dose Dense Docetaxel Following FE75C as Adjuvant Treatment of Women With Axillary Lymph Node Positive Breast Cancer Over-expressing HER2 | - | ||
| 2 | Recruiting | A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Patients With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy | - |
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"G-CSF receptor" OR ABSTRACT:"G-CSF receptor" OR TITLE:"CSF3R" OR ABSTRACT:"CSF3R") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about G-CSF receptor (CSF3R), not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/csf3r.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/csf3r.json. Licence CC BY-NC 4.0.